Hang Zhao, Zhi Li, Da Liu, Jiaxun Zhang, Zhicheng You, Yuzhang Shao, Hongyan Li, Jun Yang, Xiang Liu, Miaozhu Wang, Chengen Wu, Jing Chen, Jianwu Wang, Guanyi Kong, Libo Zhao
{"title":"PlexinA1(PLXNA1)作为细胞外囊泡工程的新型支架蛋白。","authors":"Hang Zhao, Zhi Li, Da Liu, Jiaxun Zhang, Zhicheng You, Yuzhang Shao, Hongyan Li, Jun Yang, Xiang Liu, Miaozhu Wang, Chengen Wu, Jing Chen, Jianwu Wang, Guanyi Kong, Libo Zhao","doi":"10.1002/jev2.70012","DOIUrl":null,"url":null,"abstract":"<p>Extracellular vesicles (EVs) had been described as a next-generation drug delivery system, due to the compelling evidence that they can facilitate the transfer of a variety of biomolecules between cells. The most frequently used strategy for loading protein cargoes is the endogenous engineering of EVs through genetic fusion of the protein of interest (POI) and scaffold proteins with high EV-sorting ability. However, the lack of scaffold proteins had become a major issue hindering the promotion of this technology. Herein, we proposed novel screening criteria that relax the inclusion requirement of candidate scaffold proteins and eventually identified a new scaffold protein, PLXNA1. The truncated PLXNA1 not only inherits the high EV-sorting ability of its full-length counterpart but also allows the fusion expression of POI in both outer surface and luminal areas, individually or simultaneously. In conclusion, our screening criteria expanded the range of potential scaffold proteins. The identified scaffold protein PLXNA1 showed great potential in developing therapeutic EVs.</p>","PeriodicalId":15811,"journal":{"name":"Journal of Extracellular Vesicles","volume":"13 11","pages":""},"PeriodicalIF":15.5000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541859/pdf/","citationCount":"0","resultStr":"{\"title\":\"PlexinA1 (PLXNA1) as a novel scaffold protein for the engineering of extracellular vesicles\",\"authors\":\"Hang Zhao, Zhi Li, Da Liu, Jiaxun Zhang, Zhicheng You, Yuzhang Shao, Hongyan Li, Jun Yang, Xiang Liu, Miaozhu Wang, Chengen Wu, Jing Chen, Jianwu Wang, Guanyi Kong, Libo Zhao\",\"doi\":\"10.1002/jev2.70012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Extracellular vesicles (EVs) had been described as a next-generation drug delivery system, due to the compelling evidence that they can facilitate the transfer of a variety of biomolecules between cells. The most frequently used strategy for loading protein cargoes is the endogenous engineering of EVs through genetic fusion of the protein of interest (POI) and scaffold proteins with high EV-sorting ability. However, the lack of scaffold proteins had become a major issue hindering the promotion of this technology. Herein, we proposed novel screening criteria that relax the inclusion requirement of candidate scaffold proteins and eventually identified a new scaffold protein, PLXNA1. The truncated PLXNA1 not only inherits the high EV-sorting ability of its full-length counterpart but also allows the fusion expression of POI in both outer surface and luminal areas, individually or simultaneously. In conclusion, our screening criteria expanded the range of potential scaffold proteins. The identified scaffold protein PLXNA1 showed great potential in developing therapeutic EVs.</p>\",\"PeriodicalId\":15811,\"journal\":{\"name\":\"Journal of Extracellular Vesicles\",\"volume\":\"13 11\",\"pages\":\"\"},\"PeriodicalIF\":15.5000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541859/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Extracellular Vesicles\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jev2.70012\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Extracellular Vesicles","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jev2.70012","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
细胞外囊泡(EVs)被描述为下一代药物输送系统,因为有令人信服的证据表明,EVs 可以促进各种生物分子在细胞间的转移。装载蛋白质货物最常用的策略是通过基因融合感兴趣的蛋白质(POI)和具有高EV分拣能力的支架蛋白来实现EV的内源性工程。然而,支架蛋白的缺乏已成为阻碍这一技术推广的主要问题。在此,我们提出了新的筛选标准,放宽了候选支架蛋白的纳入要求,并最终确定了一种新的支架蛋白--PLXNA1。截短的 PLXNA1 不仅继承了全长蛋白的高 EV 分类能力,还能在外层表面和管腔区域单独或同时融合表达 POI。总之,我们的筛选标准扩大了潜在支架蛋白的范围。鉴定出的支架蛋白 PLXNA1 在开发治疗性 EV 方面显示出巨大的潜力。
PlexinA1 (PLXNA1) as a novel scaffold protein for the engineering of extracellular vesicles
Extracellular vesicles (EVs) had been described as a next-generation drug delivery system, due to the compelling evidence that they can facilitate the transfer of a variety of biomolecules between cells. The most frequently used strategy for loading protein cargoes is the endogenous engineering of EVs through genetic fusion of the protein of interest (POI) and scaffold proteins with high EV-sorting ability. However, the lack of scaffold proteins had become a major issue hindering the promotion of this technology. Herein, we proposed novel screening criteria that relax the inclusion requirement of candidate scaffold proteins and eventually identified a new scaffold protein, PLXNA1. The truncated PLXNA1 not only inherits the high EV-sorting ability of its full-length counterpart but also allows the fusion expression of POI in both outer surface and luminal areas, individually or simultaneously. In conclusion, our screening criteria expanded the range of potential scaffold proteins. The identified scaffold protein PLXNA1 showed great potential in developing therapeutic EVs.
期刊介绍:
The Journal of Extracellular Vesicles is an open access research publication that focuses on extracellular vesicles, including microvesicles, exosomes, ectosomes, and apoptotic bodies. It serves as the official journal of the International Society for Extracellular Vesicles and aims to facilitate the exchange of data, ideas, and information pertaining to the chemistry, biology, and applications of extracellular vesicles. The journal covers various aspects such as the cellular and molecular mechanisms of extracellular vesicles biogenesis, technological advancements in their isolation, quantification, and characterization, the role and function of extracellular vesicles in biology, stem cell-derived extracellular vesicles and their biology, as well as the application of extracellular vesicles for pharmacological, immunological, or genetic therapies.
The Journal of Extracellular Vesicles is widely recognized and indexed by numerous services, including Biological Abstracts, BIOSIS Previews, Chemical Abstracts Service (CAS), Current Contents/Life Sciences, Directory of Open Access Journals (DOAJ), Journal Citation Reports/Science Edition, Google Scholar, ProQuest Natural Science Collection, ProQuest SciTech Collection, SciTech Premium Collection, PubMed Central/PubMed, Science Citation Index Expanded, ScienceOpen, and Scopus.